Traws Pharma (Traws Pharma) Capital Expenditure : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Traws Pharma's cash flow for capital expenditures for the three months ended in Dec. 2023 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Traws Pharma Capital Expenditure Historical Data

The historical data trend for Traws Pharma's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Capital Expenditure Chart

Traws Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capital Expenditure

Get a 7-Day Free Trial

-0.06

-0.02

-0.01

Traws Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Capital Expenditure	Get a 7-Day Free Trial															-	-	-	-	-

Traws Pharma Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Traws Pharma (Traws Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

0T2:Germany

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Executives

Victor M Moyo	officer: CHIEF MEDICAL OFFICER	12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke	director	12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja	director	12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler	officer: VP Corp Dev & Gen Counsel	C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman	officer: Chief Medical Officer	375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino	director	C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md	officer: Chief Medical Officer	C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin	officer: Chief Accounting Officer	375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker	director	375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman	director	1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy	director	375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman	director	C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta	director	OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P	10 percent owner	150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022